Our mission is to transform individual lives and fundamentally change the way diseases are managed, interpreted, and prevented. We believe that challenging something is the best way to change it.
registration | PricingREGISTER BY CREDIT CARD
|Workshops - 90-Minute||$50.00||$100.00||$25.00|
|Workshops - 120-Minute||$75.00||$150.00||$25.00|
All payments must be made in USD ($) to ensure that the full amount is received. Entry to the conference will not be permitted unless full payment has been received.
Written cancellations received via email to firstname.lastname@example.org by May 10th will be refunded less a $50 administrative fee. There will be no refunds issued after May 10th. Failure to attend without notice will not result in a refund.
Program | At a GlanceWe are delighted to release the provisional program for the 42nd annual meeting of the Society which will be held virtually and will run 17-20 May. The theme for the 42nd Annual Meeting is "Advancing Rigorous and Ethical Trials in the Pandemic Era". The Program includes two exciting keynote talks, over 20 thematic sessions and over 100 contributed presentations on diverse topics. Contributors come from a wide range of backgrounds and disciples representing the range of stakeholders in clinical trial research and conduct. Clicking on the bold red titles will download session details where available. Please note that the program is not fully confirmed and speakers and timing particularly within individual sessions may be subject to some change. Note all times are Eastern.
|SCT Annual Meeting - Monday, May 17, 2021|
|9:00 - 10:00||New Member Welcome & Orientation Session|
|10:00 - 11:30||
Welcome - SCT President - Dr. Susan Halabi
Founders Lecture Keynote
Dr. Lane - Conducting Clinical Research In The Setting Of An Outbreak: From HIV To Ebola To Covid-19
|11:30 - 12:30||Session Proposal 1
Seema Shah & Charles Weijer
Ethics and future of human challenge trials with SARS-CoV-2 to speed vaccine development
|Session Proposal 2
Managing Pragmatic Clinical Trials in the Time of COVID-19
|Session Proposal 3
Design, Implementation, and Analysis of N-of-1 Clinical Trials
|Session Proposal 4
SCT Committee Updates
|12:30 - 1:00||Lunch|
|1:00 - 2:00||Contributed Sessions 1
Statistical Design I
|Contributed Sessions 2
Statistical Analysis I
|Contributed Sessions 3
Data Management I
|Contributed Sessions 4
Study Co-ordination I
In-Conference Workshop 1
Mary Redman & Susan Halabi
Biomarker Driven Trials for Precision Medicine
|2:00 - 3:00||Session Proposal 6
Design and Implementation of a Vaccine Trial in a Pandemic – mRNA-1273 Phase I Trial
|Session Proposal 7
Different Clinical Trial Analyses for Different Stakeholders
|Session Proposal 8
Leveraging External Evidence in Clinical Research using Novel Statistical Methods
|Session Proposal 9
Benefit-Risk Assessment in Clinical Trials with Individual Patient Needs in Mind
|3:00 - 3:30||Networking|
|SCT Annual Meeting - Tuesday, May 18, 2021|
|10:00 - 11:30||
Curtis Meinert Keynote
Professor Martin Landray - “Better Trials for Better Health”
|11:30 - 12:30||Session Proposal 10
Adaptive COVID-19 Treatment Trial (ACTT) Data Management: Ensuring Success in a Constantly-Evolving, High-Demand Pandemic Environment
|Session Proposal 11
Sample size re-estimation: Reflections on implementation and extensions to complex designs
|Session Proposal 12
The ASPIRE guidance on surgical placebo controls in randomised trials
|Session Proposal 13
INCREASING DIVERSITY IN CARDIOVASCULAR CLINICAL TRIALS: ENGAGEMENT, RECRUITMENT, LEADERSHIP
|12:30 - 1:00||Lunch|
|1:00 - 2:00||
Chalmers Student Scholarship Finalists:
|Contributed Sessions 5
Statistical Design II
|Contributed Sessions 6
|Contributed Sessions 7
Study Co-ordination II
In-Conference Workshop 2
Design Clinical Trials with Multiple Endpoints: Methods and Applications
|2:00 - 3:00||Session Proposal 14
Bayesian Modeling in COVID-19 – Disease Modeling, Therapeutics, and Vaccines
|Session Proposal 15
The Impact of COVID-19 on the Conduct of Trials in the NeuroNEXT Network
|Session Proposal 16
Pragmatic trials: key unresolved ethical issues and the need for guidance
|Session Proposal 17
SCT New Committees and DMC Training Initiative
|3:30||Reception for all members|
|SCT Annual Meeting - Wednesday, May 19, 2021|
|9:00 - 10:00||Presentation of the Class of 2021 Fellows|
|10:00 - 11:00||Contributed Sessions 8
Statistical Analysis II
|Contributed Sessions 9
Statistical Design III
|Contributed Sessions 10
|Contributed Sessions 11
Study conduct during COVID-19
In-Conference Workshop 3
Designing Clinical Research to Inform Decision-Making using Value of Information
|11:00 - 12:00||Session Proposal 18
Design and Implementation of Clinical Trials in a Pandemic – Reflecting on the ACTT Studies
|Session Proposal 19
recent developments in quantitative benefit-risk assessment in clinical trials
|Session Proposal 20
It Can Be Done! Equitable, Accessible, and Efficient Clinical Trials Through Streamlined Protocol Designs and Requirements
|Contributed Sessions 12
Statistical Analysis III
|12:00 - 1:00||Business Meeting with Lunch|
|1:00 - 2:00||Contributed Sessions 13
Statistical Design IV
|Contributed Sessions 14
Statistical Analysis IV
|Contributed Sessions 15
|Contributed Sessions 16
Study Co-ordination III
In-Conference Workshop 4
Essentials of Clinical Trials
|2:00 - 3:00||Session Proposal 21
Challenges and Best Practices for Recruitment and Retention During the COVID Pandemic
|Session Proposal 22
Current issues in the design and analysis of COVID-19 vaccine efficacy trials
|Session Proposal 23
Choices, choices: Selecting, defining, and measuring outcomes for young people with depressive disorders
|Session Proposal 24
Challenges with COVID-19 Vaccine Development and Assessing Impact of the Pandemic on Oncology Trial Outcomes
|SCT Annual Meeting - Thursday, May 20, 2021|
|9:30 - 10:00||Pre-recorded talks Q&A - Session 1|
|10:00 - 11:30||
Trial of the Year
|11:30 - 12:30||Session Proposal 25
Impact of the COVID-19 Pandemic on the Design, Operations and Analysis Plans of Dementia Trials
|Session Proposal 26
Design and conduct of pilot and feasibility trials: focus on unresolved issues
|Session Proposal 27
Missing Data in Clinical Trials: principles, planning, prevention
|Session Proposal 28
Operational Innovations in Academic Data Analysis and Coordinating Centers
|12:30 - 1:00||Lunch|
|1:00 - 2:00||Contributed Sessions 17
Statistical Design V
|Contributed Sessions 18
Data Management II
|Contributed Sessions 19
|In-Conference Workshop 5
How the estimand addendum to the ICH E9 guideline helps structure clinical objectives, analyses, and conclusions – a series of oncology case studies
|In-Conference Workshop 6
Accelerating evidence generation through quality by design
|2:00 - 3:00||Contributed Sessions 20
|Contributed Sessions 21
Study Co-ordination IV
|3:00 - 3:30||Pre-recorded talks Q&A - Session 2|
|3:00 - 4:00||End of meeting|
Frequently | Asked
Have a question? If you do not find the answer in our most frequently asked questions
below, please reach out to us at email@example.com.
To request an Invitation Letter for the SCT Annual Meeting, please send a request to KellyBurns@sctweb.org after you have completed your registration and received a Meeting Confirmation/Receipt. The letter is subject to approval by office staff and will be sent to you by email.
You must be registered for the Annual Meeting to receive a letter.
Please note that is it your responsibility to check the Visa Entry Regulations into the USA. Further information can be found by clicking here.
Exhibition | Sponsors
If you are interested in becoming a Corporate Sponsor for our 2021 Virtual Annual Meeting, or for more information on the Sponsorship options available, please download the prospectus here or contact us at firstname.lastname@example.org.
Thank You to Our 2020 Corporate Sponsors!
Frontier Science Foundation is a not-for-profit research organization dedicated to the improvement of data management and statistical quality in clinical trials and medical research.
The GW Biostatistics Center has a 47 year history of leadership in practice-changing clinical trials and biostatistical methodology research. Center research has been recognized in reports to the US President and Congress and resulted in over 60 NEJM publications.
For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.
Amgen strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives. In everything we do, we aim to fulfill our mission to serve patients. And every step of the way, we are guided by the values that define us.
Berry Consultants is a statistical consulting company specializing in innovative clinical trial design, Bayesian analysis, adaptive clinical trial execution, and simulation software solutions for the pharmaceutical and medical device industry.
Emmes collaborates with clients to produce valued, trusted scientific research. We are passionate about making a difference in the quality of human health, and have supported more than a thousand studies across a diverse range of diseases since our formation in 1977.
The Jaeb Center for Health Research was established in 1993 as a freestanding, nonprofit coordinating center for multi-center clinical trials and epidemiologic research. The Jaeb Center's focus is eye disorders or type 1 diabetes.
The Oxford Recovery Model develops a targeted healing approach for each unique patient. We employ numerous therapies and healing modalities to treat a wide range of conditions.
The Data Coordinating Center (DCC) is a component of the Clinical Trials Program in the Department of Biostatistics and Medical Informatics at the UW School of Medicine and Public Health. The DCC supports investigator-initiated NIH or industry-sponsored RCTs. We provide expertise in planning, conduct, monitoring, and analysis of clinical trials.
Xeris Pharmaceuticals is a specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. XeriSol™ and XeriJect™ can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system. Learn more at www.xerispharma.com
Statistics Collaborative is dedicated to developing research programs with scientific rigor and statistical validity. For more than 30 years, our clients have relied on us for careful thought, meticulous attention to detail, and expertise across a range of statistical methods and therapeutic areas.